Close Menu

Takara Bio

NEW YORK (GenomeWeb) – WaferGen Biosystems announced today that it has completed an offering of common stock and warrants that brought in gross proceeds of $20 million.

NEW YORK (GenomeWeb) – WaferGen Biosystems today priced a public offering of stock and warrants that is expected to bring in gross proceeds of $20 million.

WaferGen Biosystems said this week that it has appointed Keith Warner as chief operating officer and Michael Henighan as CFO.

NEW YORK (GenomeWeb) – WaferGen Biosystems reported after the close of the market Thursday that its second quarter revenues rose over 600 percent and that its net loss was down 38 percent compared with the year-ago period.

NEW YORK (GenomeWeb) – WaferGen Biosystems today announced a partnership with Molecular Pathology Laboratory Network to develop next-generation sequencing-based clinical tests.

NEW YORK (GenomeWeb) – Cellectis today announced it is selling its stem cell-focused subsidiary Cellectis AB to Takara Bio for an undisclosed amount.

WaferGen Biosystems said last week that it has appointed Ivan Trifunovich as chairman of the board. Trifunovich currently serves as the company's president and CEO.

NEW YORK (GenomeWeb) – An international team of academic and industry researchers this week published the results of a comparison of commercially available platforms for microRNA expression analysis, finding that each has its own strengths and shortcomings that should be considered before selecti

NEW YORK (GenomeWeb) – WaferGen Biosystems said after the close of the market on Monday that it has effected a one-for-10 reverse stock split as it seeks to list its shares on the Nasdaq Capital Market.

NEW YORK (GenomeWeb) – WaferGen Biosystems has filed with regulators to offer up to $40 million of its common stock.

Pages

The Guardian reports that visa costs could prevent scientists and others from coming to the UK.

The Trump Administration is reconsidering its plan to issue an executive order to require federally funded research to be freely available upon publication, Times Higher Education reports.

Nature News says some preprint repositories may close down due to a lack of funds to cover costs.

In Nature this week: framework for analyzing cancer mutational signatures, treatment resistance in small cell lung cancer followed by increased intratumoral heterogeneity, and more.